Генотипический и фенотипический полиморфизм N-ацетилтрансфераз в роли предикторов бронхолегочных заболеваний

1. Бориско А.С., Моргулис О.Г, Яковлева О.А. Состояние процессов ацетилирования у больных с синдромом бронхоспазма. Пульмонология. Респ. Межведомств. сб. 1991; 10: 56-57.

2. Иванова В.В., Аксенов О.А., Кветная А.С. и др. Вируснобактериальные ассоциации и их роль в формировании бронхолегочных заболеваний у детей. Педиатрия 1992; 4-6: 8-12.

3. Ивчик Т.В., Кокосов А.Н., Буловская Л.H. и др. N-ацетилтрансфераза (NAT) — предрасполагающий фактор к развитию хронической обструктивной болезни легких (ХОБЛ). Пульмонология 1998; Прил.: Международный конгресс Интерастма- 98, Москва 20-21 окт. 1998. VIII Национальный конгресс по болезням органов дыхания. Сб. рез.: 440.

4. Кокосов А.Н., Ивчик Т.В., Буловская Л.H. и др. Определение фенотипа N-ацетилтрансферазы по интенсивности ацетилирования у больных хронической обструктивной болезнью легких. Там же. 204.

5. Ляхович В.В., Вавилин В.А., Гупгкина И.И. и др. Фармакологический и фармакогенетический подходы к проблемам патогенеза и фармакотерапии экологически обусловленных заболеваний. В кн.: V Российский нац. конгресс "Человек и лекарство". М.; 1998. 334.

6. Родцевич О.Г. Роль гено- и фенотипических маркерных систем в прогнозе детской астмы. В кн.: 7-й Национальный конгресс по болезням органов дыхания. М.; 1997. 82.

7. Рудинский К.А., Буловская Л.Н., Линцов А.Е. Характеристика активности полиморфной N-ацетилтрансферазы у больных бронхиальной астмой. Там же. 120.

8. Яковлева О.А., Косован А.И., Пентюк А.А. Индивидуальные особенности ацетилирования тест-препаратов при бронхообструктивном синдроме. В кн.: Клиническая фармакология - 25 лет: Материалы международной конф. М.; 1997. 96.

9. Agendes J.A., Marthnez С., Olivera М. et al. Identification and prevalens study of 17 allelic variants of the human NAT2 gene in a white population. Pharmacogenetics 1996; 6(5): 423-428.

10. Ambrosone C.B., Freudenheim J.L.., Graham S. et al. Cigarrette smoking, N-acetyltrasferase 2 genetic polymorphisms and breast cancer risk. J.A.M.A. 1996; 276 (18): 1494-1501.

11. Badawi A.F., Stern S.J., Lang N.P. et al. Cytochrome P-450 and acetyltransferase expression as biomarkers of carcinogenDNA adduct levels and human cancer susceptibility. Progr. Clin. Biol. Res. 1996; 395: 109-140.

12. Bell D.A., Taylor J.A., Butler M.A. et al. Genotype/phenotype discordans for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in AfricanAmericans. Carcinogenesis 1993; 14 (8): 1689-1692.

13. Boobis A.R. Molecular basis for differences in suspectibility to toxicants: introduction. Toxicol. Lett. 1992; 64-65 (spec. No): 109-113.

14. Bosso S.A., Liu Q., Evans W.E. et al. CYP2D6, N-acetylation and xanthine oxidase activity in cystic fibrosis. Pharmacotherapy 1996; 16 (5): 749-753.

15. Carr A., Gross A.S., Hoskins J.M. et al. Acetylation genotype and cutaneous hypersensitivity to trimethoprim-sulfamethoxazole in HIV-infected patients. AIDS 1994; 8 (3): 333-337.

16. Carrillo J.A., B enthez 3. Caffein metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways. Clin. Pharmacol. Ther. 1994; 55 (3): 293-304.

17. Cascorbi I., Brockm yller J., M rozikiew icz P.M. et al. Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer. Cancer Res. 1996; 56(17): 3961-3966.

18. Cofta S., Lowiski Z., M ynarczyc W. Acetylation phenotype in patients with lung cancer. Pneumonol. Alergol. Pol. 1995; 63 (7-8): 407-409.

19. Cribb А.Б., Isbruker K., Levatte T. et al. Acetylator phenotyping: the urinary caffein metabolite ratio in slow acetylators correlates with a marker of systemic NAT1 activity. Pharmacogenetics 1994; 4 (3): 166-170.

20. Dargel K. Metabolism of leukotrienes is impaired in hepatocytes from rats with thioacetamide-induced liver cirrhosis. Prostagland. Leucot. Essent. Fatty Acids. 1995; 53(4): 309-314.

21. Deguchi T. Molecular pharmacology of polymorphic aryiamine N-acetyltransferase involved in the metabolism of aryiamine drugs. Nippon Rinsho 1992; 50 (4): 877-886.

22. Denzlinger C., Haberl C., Wilmanns W. Cystenyl leukotriene production in anaphylactic reactions. Int. Arch. Allergy Immunol. 1995; 108(2): 158-164.

23. Dietrich A, Kawakubo Y., Rzany B. et at. Low N-acetylating capacity in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Exp. Dermatol. 1995; 4 (5): 313-316.

24. Goldstein J.A., Faletto M.V. Advances in mechanisms of activation and deactivation of environmental chemicals. Environ. Hlth Perspect. 1993; 100: 169-176.

25. Hamelin B.A., Xu K., Vally F. et al. Caffeine metabolism in cystic fibrosis: enhansed xanthine oxidase activity. Ibid. 56 (5): 521-529.

26. Hein D.W ., Doll M .A., Rustan T.D. et al. Metabolic activation and deactivation of aryiamine carcinogens by human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 1993; 14 (8): 1633-1638.

27. Hickman D., Risch A., Bell D.A. et al. Chromosomal localization of human genes for aryiamine N-acetyltransferase. Biochem. J. 1994; 297 (pt 3): 441-445.

28. Hirvonen A., Saarikoski S.T., Linnainmaa K. et al. GlutationS-transferase and N-acetyltransferase genotypes and asbestosassociated pulmonary disoder. J. Natl. Cancer Inst. 1996; 88 (24): 1853-1856.

29. Hou S.M ., Lambert B., Hemminski K. Relationship between mutant frequency, aromatic DNA adducts and genotypes for GSTM1 and NAT2 in bus maintenance workers. Carcinogenesis 1995; 16 (8): 1913-1917.

30. Hsu K.Y., Song D.J., Ho Y. The influence of pyruvic acid the phnrmacokinetics of sulphadiazine in rabbits. Biopharm. Drug Dispos. 1995; 16 (3): 233-244.

31. Hussein E., Yamamah O., Saleh A. Glucose-6-phosphate dehydrogenase defiscency and sulfadimidin acetylation phenotypes in Egyptian oases. Biochem. Genet. 1992; 30 (3-4): 113-121.

32. Hutabarat B.M., Sm ith A.L., Unadkat D.J. Disposition of drugs in cystic fibrosis, VII. Acetylation of sulphamethoxazol in blood cells: in vitro-in vivo correlation and characterzation of its kinetics of acetylation in lymphocytes. Clin. Pharmacol. Ther. 1994; 55(4): 427-433.

33. Ilett K.F, Chiswell O.M., Spargo K.M. et al. Acetylation phenotype and genotype in aboriginal leprosy petiens from the north-west region of Western Australia. Ibid. 1993; 3 (5): 264-269.

34. Kaufmann G.R., Wenk M., Taeschner W. et al. N-acetyltransferase 2 polymorphism in patients infected with human immunodefisiency virus. Clin. Pharmacol. Ther 1996; 60 (1): 62-67.

35. Lin H J., Han C. Y., Lin B.K. et al. Ethnie distribution of slow acetylator mutation in the polymorphic N-acetyltransferase (NAT2) gene. Ibid. 1994; 4 (3): 125-134.

36. Magazine H.I., Malik A.B., Beuner C.A. et al. Acetylated endotelin-l is a constrictor in guinea pig lung vasculature but not in isolated vascular strips. J. Pharmacol. Exp. Ther. 1992; 260 (2): 632-636.

37. Marthnez C., Agendez J.A., Olivera M et al. Lung cancer and mutations at the polymorphic NAT2 gene locus. Pharmacogenetics 1995; 5 (4): 207-214.

38. Mathelier-Fusade P., Leynadier F. Intolerance to sulfonamides in HIV infected subjects. Toxic and allergic origin. Presse Med. 1993; 22 (29): 1363-1365.

39. Meyer U.A. Polymorphism of human acetyltransferases. Ibid. 1994; 102 (suppl.6): 213-216.

40. Mrosikievicx P.M., Cascorbi I., Roots I. et al. Determination and allelic allocation of seven nucleotide transitions within the aryiamine N-acetyltransferase gene in the Polish population. Clin. Pharmacol. Ther. 1996; 59 (4): 376-382.

41. Hebert D.W ., McKinnon R.A., Puga A. Human drug-metabolizing enzyme polymorphisms: effects on risk of tox

42. Nerurkar P.V., Schut H.A., Anderson L.M. et al. Ahr locus phenotype in congenic mice influences hepatic and pulmonary DNA adduct levels of 2-amino-3-methylimidazo [4,5-f] quinoline in the absence of cytochrome P450 induction. Mol. Pharmacol. 1996; 49 (5): 874-881.

43. O'Brien P.J., Hales B.F., Josephy P.D. et al. Chemical carcinogenesis, mutagenesis and teratogenesis. Can. J. Physiol. Pharmacol. 1996; 74 (5): 565-571.

44. Oyama Т., Kawamoto Т., Mizoue T. et al. N-acetylation polymorphism in patients with lung cancer and its association with p53 gene mutation. Anticancer Res. 1997; 17 (18): 577-581.

45. Pontes Z.B., Vinsent-Viry М., Gueguen K. et al. Acetylation phenotypes and biological variation in a French Caucasian population. Eur. J. Clin. Chem. Clin. Biochem. 1993; 31 (2): 59-68.

46. Rashid J.R., Kofi-Tsepko, Juma F.D. Acetylation status using hydralazine in African hypertensives at Kenyatta National Hospital. East Afr. Med. J. 1992; 69 (7): 406-408.

47. Raunio H., Husggafvel-Pursiainen K., Anttila S. et al. Diagnosis of polymorphysms in carcinogen-activating and inactivating enzymes and cancer susceptibility — a reivew. Gene 1995; 159 (1): 113-121.

48. Roots I., Brockmyller J., Drakoulis N. et al. Mutant genes of cytochrome P-450IID6, glutathion S-transferase class Mu and aryiamine N-acetyltransferase in lung cancer patients. J. Clin. Invest. 1992; 70 (3—4): 307-319.

49. Rothman М., Hayers R.B., Bi W: et al. Correlation between Nacetyltransferase activity and NAT2 genotype in Chinese males. Pharmacogenetics 1993; 3 (5): 250-255.

50. Rothman N., Hayers K.B. Using biomarkers of genetic susceptibility to enhance the study of cancer etiology. Environ. Hlth Perspect. 1995; 103 (suppl.8): 291-295.

51. Sardas S., Lahijany B., Cok I. et al. N-acetylation phenotyping with sulfamethazine in an Iranian population. Pharmacogenetics 1993; 3 (3): 131-134.

52. Sinclair J., Sim E. A fragment consisting of first 204 amino-terminal aminoacids of human aryiamine N-acetyltransferase one (NAT1) and the first transacetylation step of catalysis. Biochem. Pharmacol. 1997; 53 (1): 11-16.

53. Sinues B., Ruena P., Benthez J. et al. Thioether excretion, urinary mutagenicity and metabolic phenotype in smokers. J. Toxicol. Environ. Hlth 1994; 43 (3): 327-338.

54. Soon S.L., Mazuruk K., Bernard M. et al. The human serotonin N-acetyltransferase (EC 2.3.1.87) gene (AANAT): structure, chromosomal localization and tissue expression. Genomics 1996; 34 (1): 76-84.

55. Vatsis K.P., Weber W.W., Bell D.A. et al. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995; 5 (1): 1-17.

56. Vineis P., Landi M .T., Caporaso N. Metabolic polymorphysm and the cancer risk: the evaluation of epidemiological studies. Med. J. Lavoro. 1992; 83 (6): 557-575.

57. Vineis P., Schulte P.A. Scientific and ethical aspects of genetic screening of workers for cancer risk the case of the N-acetyltransferase phenotype. J. Clin. Epidemiol. 1995; 48 (2): 189-197.

58. Watanabe M. Genetic and phenotypic polymorphysms in carcinogen-metabolizing enzymes and cancer susceptibility. Nippon Rinsho 1996; 54 (8): 2261-2275.

59. Weber W.W. Influence of heredity on human sensitivity to environmental chemicals. Environ. Mol. Mutagen. 1995; 25(suppl.26): 102-114.

60. Yadav S.P., Rawitch A.B. Effect of peptide acetylation on its interaction with antipeptide antibody. Biochem. Biophys. Res. Commun. 1994; 205 (3): 1688-1695.

61. Yasunara H. Ethnic factors in evaluation of drug efficacy and safety // Nippon Yagurigaku Zasshi 1994; 104 (2): 67-78.

62. Yiamouyiannis C.A., Sanders B.A., W atkins J.B. et a l . Chronic physical activity: hepatic hypertrophy and increased total biotransformation enzyme activity. Biochem. Pharmacol. 1992; 44 (1): 121-127.

63. Zaher H., Svensson C.K. Glucocorticoid induction of hepatic acetyl-CoA:arylamine N-acetyltransferase activity in the rat. Res. Commun. Chem. Pathol. Pharmacol. 1994; 83 (2): 195-208.